Tags

Type your tag names separated by a space and hit enter

Gene therapy: Have the risks associated with viral vectors been solved?

Abstract

Gene therapy has the potential to cure monogenic diseases through the replacement of the deleterious gene with a functional copy. While the field of gene therapy has been plagued by serious adverse events associated with therapy, it is hoped that new, safer viral vectors have reduced these risks greatly. However, recently published reports indicate that these new viral vectors are a potential risk to patients receiving gene therapy. Thus, caution is required when recruiting patients for clinical trials of gene therapies to ensure the benefit of the therapy outweighs the risks.

Authors

Source

MeSH

Genetic Therapy
Genetic Vectors
Humans
Risk Assessment
Risk Factors
Viruses

Pub Type(s)

Editorial

Language

eng

PubMed ID

21280375

Citation

Auman, J Todd. "Gene Therapy: Have the Risks Associated With Viral Vectors Been Solved?" Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 637-8.
Auman JT. Gene therapy: Have the risks associated with viral vectors been solved? Curr Opin Mol Ther. 2010;12(6):637-8.
Auman, J. T. (2010). Gene therapy: Have the risks associated with viral vectors been solved? Current Opinion in Molecular Therapeutics, 12(6), pp. 637-8.
Auman JT. Gene Therapy: Have the Risks Associated With Viral Vectors Been Solved. Curr Opin Mol Ther. 2010;12(6):637-8. PubMed PMID: 21280375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gene therapy: Have the risks associated with viral vectors been solved? A1 - Auman,J Todd, PY - 2011/2/2/entrez PY - 2011/2/2/pubmed PY - 2011/5/20/medline SP - 637 EP - 8 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - Gene therapy has the potential to cure monogenic diseases through the replacement of the deleterious gene with a functional copy. While the field of gene therapy has been plagued by serious adverse events associated with therapy, it is hoped that new, safer viral vectors have reduced these risks greatly. However, recently published reports indicate that these new viral vectors are a potential risk to patients receiving gene therapy. Thus, caution is required when recruiting patients for clinical trials of gene therapies to ensure the benefit of the therapy outweighs the risks. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21280375/Gene_therapy:_Have_the_risks_associated_with_viral_vectors_been_solved L2 - https://medlineplus.gov/genesandgenetherapy.html DB - PRIME DP - Unbound Medicine ER -